The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News
in Numbers

17

Chinese authorities have approved the first Alzheimer’s drug in 17 years

Three

AstraZeneca has announced three large-scale initiatives in China, including the creation of a new global R&D centre, an AI innovation centre, and a healthcare industrial fund with China International Capital Corporation Limited

$434m

Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to $434m

2023

The year that the CPhI Annual Report predicts Europe will surpass the US in biologic manufacturing capacity

80.2%

Promising phase III results from Takeda show its dengue vaccine was 80.2% effective in patients involved in the study

Data:
News
in Numbers

17

Chinese authorities have approved the first Alzheimer’s drug in 17 years

$434m

Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to $434m

2023

The year that the CPhI Annual Report predicts Europe will surpass the USA in biologic manufacturing capacity

Three

80%

Promising phase III results from Takeda show its dengue vaccine was 80.2% effective in patients involved in the study.

Roche drops myostatin inhibitor for DMD

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor.

Source: Pharmaphorum

Gilead sued over PrEP-focused HIV patent

The US Department of Health and Human Services is suing Gilead for patent infringement, saying the company and its HIV prophylaxis meds Truvada and Descovy reaped profits off hundreds of millions of dollars in taxpayer-funded research.

Source: Fierce Pharma

NICE backs first cannabis-based drugs

Two cannabis-based medicines have been approved for use on the NHS in England for the first time, and will be used to treat patients with epilepsy and multiple sclerosis.

Source: PM Live

J&J seeks European approval of its Ebola vaccine

Johnson & Johnson has filed for approval from European regulators for its two-dose experimental vaccine to protect against Ebola.

Source: Aljazeera

Approvals

REBLOZYL (luspatercept-aamt)

Celgene Corporation and Acceleron Pharma Inc announced the US FDA has approved REBLOZYL for the treatment of anaemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Source: Celgene

UVADEX (Methoxsalen)

The Therapeutic Goods Administration in Australia approved Uvadex for use with the THERAKOS CELLEX Photopheresis System for treatment of chronic graft versus host disease and skin manifestations of cutaneous t-cell lymphoma in adults..

Source: Mallinckrodt Pharmaceuticals

Ziextenzo (pegfilgrastim-bmez)

Sandoz has received US FDA approval for Ziextenzo, which is Indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy.

Source: Novartis